Tyrosine kinase inhibitors for chronic myelogenous leukemia [5]

New England Journal of Medicine

Volumn 357, Issue 15, 2007, Pages 1557-

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; BONE MARROW EXAMINATION; DRUG ANTAGONISM; DRUG MONITORING; METHODOLOGY; NOTE;

BONE MARROW EXAMINATION; DRUG MONITORING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 35248867857     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.